ストックスクリーナーアプリを入手
89.52
1.81%
-1.65
アフターアワーズ：
89.52
前日終値:
$91.17
開ける：
$91.87
24時間の取引高:
1.38M
Relative Volume:
0.68
時価総額：
$11.87B
収益：
$982.02M
当期純損益:
$-416.28M
株価収益率:
-27.01
EPS:
-3.3148
ネットキャッシュフロー:
$-233.07M
1週間 パフォーマンス:
+7.74%
1か月 パフォーマンス:
-4.59%
6か月 パフォーマンス:
-5.82%
1年 パフォーマンス:
+103.22%
1日の値動き範囲:
$87.57
$93.00
1週間の範囲:
$79.01
$93.00
52週間の値動き範囲:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Compare GH vs TMO, DHR, IDXX, WAT, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
89.52 | 12.09B | 982.02M | -416.28M | -233.07M | -3.3148 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 繰り返されました | Canaccord Genuity | Buy |
| 2026-02-17 | 開始されました | Robert W. Baird | Outperform |
| 2026-01-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-12-02 | 再開されました | Morgan Stanley | Overweight |
| 2025-09-25 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | 再開されました | Wells Fargo | Overweight |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-01-23 | 開始されました | Barclays | Overweight |
| 2024-06-28 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-13 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-09-27 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-05-26 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-05 | 開始されました | UBS | Buy |
| 2023-03-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-11-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | 開始されました | Craig Hallum | Buy |
| 2022-10-06 | 開始されました | Stephens | Overweight |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-04-28 | 再開されました | BTIG Research | Buy |
| 2022-02-24 | 繰り返されました | Canaccord Genuity | Buy |
| 2022-02-24 | 繰り返されました | Citigroup | Buy |
| 2022-02-24 | 繰り返されました | Cowen | Outperform |
| 2022-02-24 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-24 | 繰り返されました | SVB Leerink | Outperform |
| 2022-02-24 | 繰り返されました | Stifel | Buy |
| 2022-02-24 | 繰り返されました | Wells Fargo | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-05-25 | 開始されました | Wells Fargo | Overweight |
| 2021-01-11 | 開始されました | Stifel | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-06-12 | 開始されました | BTIG Research | Buy |
| 2020-02-21 | 開始されました | Guggenheim | Buy |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-08-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-04-16 | 開始されました | Canaccord Genuity | Buy |
| 2019-04-10 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | 繰り返されました | BofA/Merrill | Neutral |
| 2018-10-29 | 開始されました | BofA/Merrill | Neutral |
| 2018-10-29 | 開始されました | JP Morgan | Overweight |
| 2018-10-29 | 開始されました | William Blair | Outperform |
すべてを表示
Guardant Health Inc (GH) 最新ニュース
Guardant Health India Launch: ₹1.4 Lakh Cancer Test par Hote Bawal? Zydus ne ki partnership! - Whalesbook
The Bull Case For Guardant Health (GH) Could Change Following New ESR1 Liquid Biopsy CDx Approval – Learn Why - Yahoo Finance
Why is Guardant Health stock falling on Tuesday? - MSN
MSN Money - MSN
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy - Benzinga
Guardant Health (GH) Receives FDA Approval for Liquid Biopsy Tes - GuruFocus
FDA approves Guardant360 CDx as companion diagnostic for VEPPANU - Investing.com
Does Guardant Health (GH) Have Long-Runway for Growth? - Insider Monkey
Guardant blood test wins FDA approval to guide VEPPANU use in breast cancer - Stock Titan
Pictet Asset Management Holding SA Sells 89,386 Shares of Guardant Health, Inc. $GH - MarketBeat
Short Interest in Guardant Health, Inc. (NASDAQ:GH) Decreases By 15.0% - MarketBeat
Director at Guardant Health (GH) exercises 154 RSUs and holds 19,362 shares - Stock Titan
Guardant Health, Inc. $GH Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Comerica Bank Grows Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill
Guardant Health (GH) Experiences 4% Decline in Midday Trading - GuruFocus
Lagoda Investment Management, L.P.'s Guardant Health Inc(GH) Holding History - GuruFocus
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform - BioSpace
INVESCO V.I. Small Cap Equity Fund's Guardant Health Inc(GH) Holding History - GuruFocus
Guardant Health partners with Nuvalent on diagnostic tests By Investing.com - Investing.com South Africa
Vanguard holds 6.59M shares of Guardant Health (NYSE: GH) — 5.02% stake - Stock Titan
Delta Investment Management LLC Buys Shares of 22,236 Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. $GH Position Trimmed by Jennison Associates LLC - MarketBeat
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Analysts Conflicted on These Healthcare Names: CareDx (CDNA), Biogen (BIIB) and Guardant Health (GH) - The Globe and Mail
Guggenheim Keeps Their Buy Rating on Guardant Health (GH) - The Globe and Mail
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market - openPR.com
Guardant Health partners with Nuvalent on diagnostic tests - Investing.com
Guardant Health Inc. announces a multi-year strategic partnership with biopharmaceutical company Nuvalent - Bitget
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Guardant Health (GH) to Release Earnings on Thursday - MarketBeat
EBITDA per share of Guardant Health, Inc. – DUS:5GH - TradingView
Guardant Health lines up three investor conference webcasts - Stock Titan
Guardant Health to Participate in Upcoming Investor Conferences - marketscreener.com
Guggenheim Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $135 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Pfizer (PFE) and Guardant Health (GH) - The Globe and Mail
Guardant Health (GH) Faces Minimal Impact from AstraZeneca Advis - GuruFocus
Guardant Health slides as FDA briefing raises questions tied to AstraZeneca camizestrant review - Quiver Quantitative
[ARS] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health (NASDAQ: GH) grows to $982M revenue and details 2026 shareholder meeting - Stock Titan
Guardant Health (GH) Shares Decline Amid FDA Concerns Over Camiz - GuruFocus
Why Is Guardant Health Stock Falling On Tuesday? - Benzinga
Canaccord reiterates Guardant Health stock rating ahead of FDA meeting By Investing.com - Investing.com South Africa
Canaccord reiterates Guardant Health stock rating ahead of FDA meeting - Investing.com
PD Small-Cap Growth Index Portfolio's Guardant Health Inc(GH) Holding History - GuruFocus
Guardant Health Announces Resignation of Chief Medical Officer - TipRanks
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care - MSN
Guardant Health, Inc. Announces Resignation of Craig Eagle, M.D. as Chief Medical Officer, Effective May 8, 2026 - marketscreener.com
CMO Craig Eagle to leave Guardant Health (NASDAQ: GH) May 8 - Stock Titan
Teachers Retirement System of The State of Kentucky Sells 13,646 Shares of Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Stock Analysis: Unpacking A 44% Potential Upside For Investors - DirectorsTalk Interviews
Guardant Health Inc (GH) 財務データ
収益
当期純利益
現金流量
EPS
0.34%
1.63%
大文字化:
|
ボリューム (24 時間):